The studies suggest that mutant KRAS signals predominantly through the rapidly accelerating fibrosarcoma (RAF) effector pathway in pancreatic ductal adenocarcinoma (PDAC) models, with its ...

Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS ...

Thus, we will focus primarily on the therapeutic targeting of the major RAS effector pathways, in addition to several essential co-opted pathways, as reviewed in the next section. MEK/CDK4 PD ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S ...